Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

68.45EUR
23 Sep 2016
Change (% chg)

€-0.48 (-0.70%)
Prev Close
€68.93
Open
€68.55
Day's High
€68.91
Day's Low
€68.12
Volume
2,351,803
Avg. Vol
2,471,432
52-wk High
€93.82
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.81
Market Cap(Mil.): €88,234.93
Shares Outstanding(Mil.): 1,289.04
Dividend: 2.93
Yield (%): 4.28

Financials

  SASY.PA Industry Sector
P/E (TTM): 21.55 36.61 36.60
EPS (TTM): 3.18 -- --
ROI: 4.96 14.46 13.91
ROE: 7.50 15.26 14.82

BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar

* Files suit in U.S. To defend paten rights on Lantus and Lantus Solostar

19 Sep 2016

UPDATE 2-Teva, Intel to develop wearable tech for Huntington's disease

Sept 15 Teva Pharmaceutical Industries Ltd said on Thursday it was collaborating with Intel Corp to develop a wearable technology platform to track the progression of disease in patients with Huntington's, a fatal degenerative disorder.

15 Sep 2016

Sanofi, Google parent form $500 million diabetes joint venture

PARIS French drugmaker Sanofi and Verily, the life sciences unit of Google parent Alphabet Inc, on Monday said they would invest about $500 million in a joint venture combining devices with services to improve diabetes care, an example of growing ties between the pharma and tech sectors.

13 Sep 2016

UPDATE 2-Sanofi, Google parent form $500 mln diabetes joint venture

PARIS, Sept 12 French drugmaker Sanofi and Verily, the life sciences unit of Google parent Alphabet Inc, on Monday said they would invest about $500 million in a joint venture combining devices with services to improve diabetes care, an example of growing ties between the pharma and tech sectors.

13 Sep 2016

Investors stay positive as corporate yields turn negative

LONDON, Sept 12 (IFR) - Investors, doing their best to remain positive even as corporate bonds descend deeper into negative yielding territory, bought two new issues with negative yields last week as the strength of central bank action continued to promote perverse incentives.

12 Sep 2016

Sanofi, Google parent in $500 million diabetes joint venture

PARIS French drugmaker Sanofi and Google owner Alphabet's life sciences firm Verily are to invest about $500 million in a diabetes joint venture combining devices with services, an example of growing ties between the pharma and tech sectors.

12 Sep 2016

French and Benelux stocks-Factors to watch on Sept 12

PARIS, Sept 12 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

12 Sep 2016

Sanofi and Alphabet set up JV in diabetes

PARIS, Sept 12 French drugmaker Sanofi and Google owner Alphabet's U.S-based life sciences company Verily, announced on Monday the launch of a joint-venture aimed at offering patients suffering from diabetes products that will combine devices and services.

12 Sep 2016

BRIEF-Sanofi and Regeneron say Praluent shows positive phase 3 trial data

* Sanofi and Regeneron say Praluent shows positive investigational data in phase 3 trial Further company coverage: (Reporting by Laurence Frost)

29 Aug 2016

Pfizer's Medivation buy seen prescribing more biotech M&A

Medivation's $14 billion sale to U.S. drug giant Pfizer Inc for a hefty premium, the largest U.S. biotechnology acquisition so far this year, had investors on Monday speculating about more dealmaking in the sector.

23 Aug 2016

Earnings vs. Estimates